Chimeric Therapeutics Launches $3.2 million Entitlement Offer to Fund Clinical Trials

Chimeric Therapeutics Limited (ASX:CHM) has announced a non-renounceable entitlement offer to raise approximately $3.2 million. The offer allows eligible shareholders to acquire two new shares for every five held at $0.005 per share, along with one option per share at an exercise price of $0.008, expiring on December 19, 2025. The funds will primarily support the CHM CDH17 Phase 1/2 clinical trial for neuroendocrine tumors, colorectal cancer, and gastric cancer, alongside the development of the CORE-NK program in collaboration with Case Western University and MD Anderson Cancer Center. The offer closes on April 8, 2025, with new shares expected to be allotted by April 15, 2025. PAC Partners Securities and Taylor Collison Limited are managing the offer, with adviser options issued for professional services.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com